Race Oncology Ltd. ((AU:RAC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. is conducting a Phase 1 clinical study titled ‘A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of RC220, a bisantrene formulation, in combination with doxorubicin for treating advanced solid tumours. This research is significant as it explores new treatment avenues for patients where anthracycline is a viable option.
The study tests RC220, administered intravenously, in combination with doxorubicin, a well-known chemotherapy drug. The goal is to determine the maximum tolerated dose and assess the safety and potential efficacy of this combination in treating solid tumours.
This open-label, non-randomized study is divided into two parts. Part 1 involves dose escalation to find the maximum tolerated dose, enrolling up to 33 patients. Part 2 is a dose expansion phase with about 20 patients, focusing on confirming safety and preliminary efficacy. The study uses a single-group intervention model without masking, primarily for treatment purposes.
The study began on January 20, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on September 1, 2025, indicating ongoing recruitment and progress.
This update could positively influence Race Oncology’s stock performance and investor sentiment, as successful results may enhance the company’s market position in oncology treatments. Investors should monitor this study’s progress, considering the competitive landscape of cancer therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.